RxDoctor Payments Data

John Little

Family · Memphis, TNNPI 1649779786

Payments from drug & device makers

$1,587in general payments, 2019–2025

Across 85 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$215
  • GSK$201
  • Novartis$172
  • Pfizer$162
  • AbbVie$120
  • Bayer$113
  • plus $604 from 14 others

What the payments were for

  • Food & beverage$1,587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,587 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$26,259
Medicare patients
157
Services billed
840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate28$48,571
JardianceEmpagliflozin48$41,049
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$32,443
FarxigaDapagliflozin Propanediol36$25,459
LinzessLinaclotide37$23,430
RybelsusSemaglutide18$20,869
OzempicSemaglutide16$15,419
MyrbetriqMirabegron24$13,376
JanuviaSitagliptin Phosphate13$12,181
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$10,121
XareltoRivaroxaban14$7,959
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,593
Spiriva HandihalerTiotropium Bromide12$5,779
Aripiprazole17$2,054
Gabapentin102$1,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$215$48,57128 claims
GSKTrelegy Ellipta, Anoro Ellipta$201$42,56456 claims
Boehringer IngelheimJardiance$48$41,04948 claims
Novo NordiskRybelsus, Ozempic$100$36,28834 claims
AstraZenecaFarxiga, Breztri Aerosphere$46$33,05348 claims
AbbVieLinzess$120$23,43037 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.

Other family in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →